182 related articles for article (PubMed ID: 28429378)
21. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program.
Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
Addiction; 2015 Aug; 110(8):1301-10. PubMed ID: 25917125
[TBL] [Abstract][Full Text] [Related]
22. Training law enforcement to respond to opioid overdose with naloxone: Impact on knowledge, attitudes, and interactions with community members.
Wagner KD; Bovet LJ; Haynes B; Joshua A; Davidson PJ
Drug Alcohol Depend; 2016 Aug; 165():22-8. PubMed ID: 27262898
[TBL] [Abstract][Full Text] [Related]
23. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
24. Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention.
Kirane H; Ketteringham M; Bereket S; Dima R; Basta A; Mendoza S; Hansen H
J Subst Abuse Treat; 2016 Oct; 69():44-9. PubMed ID: 27568509
[TBL] [Abstract][Full Text] [Related]
25. Medical providers' knowledge and concerns about opioid overdose education and take-home naloxone rescue kits within Veterans Affairs health care medical treatment settings.
Winograd RP; Davis CS; Niculete M; Oliva E; Martielli RP
Subst Abus; 2017; 38(2):135-140. PubMed ID: 28486076
[TBL] [Abstract][Full Text] [Related]
26. The implementation of a naloxone rescue program in university students.
Panther SG; Bray BS; White JR
J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
[TBL] [Abstract][Full Text] [Related]
28. Low overdose responding self-efficacy among adults who report lifetime opioid use.
Tormohlen KN; Tobin KE; Davey-Rothwell MA; Latkin C
Drug Alcohol Depend; 2019 Aug; 201():142-146. PubMed ID: 31212214
[TBL] [Abstract][Full Text] [Related]
29. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability.
Strang J; Powis B; Best D; Vingoe L; Griffiths P; Taylor C; Welch S; Gossop M
Addiction; 1999 Feb; 94(2):199-204. PubMed ID: 10396785
[TBL] [Abstract][Full Text] [Related]
30. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
Stopka TJ; Donahue A; Hutcheson M; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
[TBL] [Abstract][Full Text] [Related]
31. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.
Zang X; Walley AY; Chatterjee A; Kimmel SD; Morgan JR; Murphy SM; Linas BP; Nolen S; Reilly B; Urquhart C; Schackman BR; Marshall BDL
Addiction; 2023 Dec; 118(12):2413-2423. PubMed ID: 37640687
[TBL] [Abstract][Full Text] [Related]
32. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities.
Dietze PM; Stare M; Cogger S; Nambiar D; Olsen A; Burns L; Lenton S
Drug Alcohol Rev; 2018 May; 37(4):457-463. PubMed ID: 29744979
[TBL] [Abstract][Full Text] [Related]
33. Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs.
Oliva EM; Nevedal A; Lewis ET; McCaa MD; Cochran MF; Konicki PE; Davis CS; Wilder C
Subst Abus; 2016; 37(1):118-26. PubMed ID: 26675643
[TBL] [Abstract][Full Text] [Related]
34. Overdose Awareness and Reversal Trainings at Philadelphia Public Libraries.
Lowenstein M; Feuerstein-Simon R; Dupuis R; Herens A; Hom J; Sharma M; Sheni R; Encarnacion L; Flaherty C; Cueller M; Cannuscio C
Am J Health Promot; 2021 Feb; 35(2):250-254. PubMed ID: 32662281
[TBL] [Abstract][Full Text] [Related]
35. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
36. Opioid overdose prevention training with naloxone, an adjunct to basic life support training for first-year medical students.
Berland N; Fox A; Tofighi B; Hanley K
Subst Abus; 2017; 38(2):123-128. PubMed ID: 28027016
[TBL] [Abstract][Full Text] [Related]
37. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City.
Galea S; Worthington N; Piper TM; Nandi VV; Curtis M; Rosenthal DM
Addict Behav; 2006 May; 31(5):907-12. PubMed ID: 16139434
[TBL] [Abstract][Full Text] [Related]
38. Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.
Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
J Urban Health; 2016 Feb; 93(1):117-30. PubMed ID: 26800987
[TBL] [Abstract][Full Text] [Related]
39. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
[TBL] [Abstract][Full Text] [Related]
40. Opioid overdose and naloxone education in a substance use disorder treatment program.
Lott DC; Rhodes J
Am J Addict; 2016 Apr; 25(3):221-6. PubMed ID: 27002783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
